What Atussinum Treats: Main Uses and Benefits

Atussinum is considered relevant in contexts marked by increased discomfort related to temporary respiratory symptoms. It is used in the therapeutic domain of symptomatic management, where it supports the patient by addressing certain distressing symptoms.

The primary symptomatic applications include managing symptoms that may present as a dry, irritating, non-productive cough, and addressing cough associated with minor irritative states linked to the common cold or influenza.

“The primary benefit of this symptomatic relief is that it may assist with easing symptoms of increased neurological or muscular activity, particularly when they interfere with daily functioning.”

This medicine is commonly used across conditions presenting with acute episodes of cough, assisting with maintaining functional stability during phases when symptoms become more noticeable. The medicine is relevant for managing symptoms that interfere with daily functioning, particularly the cough that disrupts sleep. This supports the patient during difficult episodes by easing distress and helps improve day-to-day comfort.

Regulatory References

1. NIH MedlinePlus overview

Who Can and Cannot Use Atussinum?

The population eligibility for Atussinum (Dextromethorphan Hydrobromide) is determined by specific regulatory criteria, contraindications, and age limitations established in official government documents.

Populations Excluded from Use (Contraindications)

Official labeling strictly prohibits the use of Atussinum in certain populations:

• Monoamine Oxidase Inhibitors (MAOIs): Use is contraindicated if a patient is currently taking or has taken an MAOI within the preceding 14 days.
• Hypersensitivity: Individuals with a known allergy to Dextromethorphan Hydrobromide or any of the product’s excipients.
• Respiratory Risk: Patients who are in, or at risk of developing, respiratory failure.

Age-Based and Conditional Restrictions

• Children: Use is generally established for adults and children 12 years and over. However, some European regulators contraindicate use in children under 12, and US health authorities recommend that non-prescription cold products not be used in children under 4 years.
• Chronic Cough: The medicine is not recommended for a persistent or chronic cough (e.g., associated with asthma) or a cough accompanied by excessive secretions/phlegm.
• Organ Function: Caution is mandatory for patients with moderate to severe hepatic impairment or severe renal impairment due to altered drug clearance.
• Pregnancy and Lactation: Use during pregnancy and breastfeeding is not established as safe and is generally not recommended unless deemed essential after a professional risk assessment.

Interactions with Other Medicines and Products

The official interaction profile for Atussinum—a combination product—is structured around avoiding additive pharmacological effects and certain high-risk combinations.

Do Not Combine (Contraindicated):

The product must not be used concurrently with or within two weeks of stopping a Monoamine Oxidase Inhibitor (MAOI), as this combination significantly increases the risk of a severe hypertensive reaction.

Use with Caution or Avoidance:

• CNS Depressants: Concurrent use with alcohol and other Central Nervous System (CNS) depressants, including sedatives and tranquilizers, may result in increased sedation and respiratory depression. Patients are advised to avoid or strictly limit alcohol consumption.
• Other Anticholinergic Agents: Combining with other medicines that possess anticholinergic effects, such as certain antidepressants or other antihistamines, may lead to dangerously enhanced anticholinergic effects, including a serious risk of paralytic ileus.
• Antihypertensive Agents: The decongestant component may reduce the effectiveness of blood pressure-lowering medicines (antihypertensives), necessitating close blood pressure monitoring and potential dose adjustment by a healthcare provider.

Caution is also noted for concurrent use with Digitalis glycosides and Thyroid preparations due to the potential for increased cardiovascular effects.

Atussinum functions as a mathbfnon-opioid peripheral mathbfcough;suppressant, primarily modulating afferent signaling within the mathbfrespiratory;tract. The molecule acts at the level of the peripheral sensory nerve endings, specifically targeting mathbfC;fibers;and;Adelta;fibers located in the mathbftracheobronchial;mucosa. Its interaction with these nerve endings results in a mathbflocal;anesthetic;effect, characterized by the mathbfinhibition;of;voltage-gated;sodium;channels;( Nav), which are critical for action potential generation and propagation. This mathbfsodium;channel;blockade decreases the excitability of the sensory afferents. The resulting mathbfreduced;firing;rate of mathbfpulmonary;stretch;receptors and other chemoreceptors within the bronchial tree leads to a mathbfdiminished;transmission;of;afferent;impulses to the mathbfmedullary;cough;center in the brainstem. Consequently, the threshold for activating the central cough reflex circuit is mathbfelevated, leading to a systemic mathbfattenuation;of;the;cough;reflex response.

How to Use Atussinum: Official Administration Guidelines

This section outlines the usage instructions for Atussinum. These instructions define the proper method, dosage, and frequency limits for administration.

Administration Scope

Official Administration Procedure

Administration of the 5.2 mg dose requires the use of the single-dose nasal device according to the following procedure:

1. Remove the round blue tab from the blue nozzle of the nasal device.
2. Insert the blue nozzle into one nostril.
3. Squeeze the white air pump 3 separate times while inhaling through the nose.
4. The white air pump must be allowed to expand fully to its original shape between each of the three squeezes.
5. Discard the device after the 3 squeezes are complete.

Special Procedural Condition

Patients with known risk factors for coronary artery disease must undergo a cardiovascular evaluation. It is strongly recommended that the first dose administration for these patients takes place in a healthcare facility equipped with electrocardiogram monitoring.

Clinical evidence for Atussinum (Butamirate Citrate) primarily supports its use as a non-narcotic, centrally acting cough suppressant for the symptomatic treatment of non-productive cough, particularly in the context of acute respiratory tract infections like bronchitis, tracheitis, and laryngitis.

Recent randomized, controlled clinical trials have assessed the efficacy and safety of butamirate-containing products in patients with acute uncomplicated bronchitis and associated cough. Studies have indicated a significant reduction in both the frequency and severity of daytime and nocturnal cough attacks in the verum (active) group compared to placebo over a treatment course of up to ten days. For instance, a statistically significant number of participants receiving the active treatment achieved a ge 75% reduction in cough attack frequency and severity compared to the placebo group at various time points, including Days 3, 8, and 10.

• Efficacy: Butamirate is believed to act centrally on the medullary cough center, inhibiting the cough reflex. It also exhibits peripheral actions, including mild bronchodilation, which may further relieve irritation in the airways.
• Safety Profile: Clinical data generally show butamirate to be well-tolerated. Reported adverse events are typically rare (ge 1/10,000 to <1/1,000) and mild, often including nausea, dizziness, diarrhea, drowsiness, and occasionally urticaria or hypersensitivity reactions. The non-opioid nature of the drug means it is not associated with the risk of dependence or significant respiratory depression seen with opioid-based antitussives.

While the drug is considered effective for dry, irritative coughs, some studies comparing butamirate to other antitussives or placebo have produced mixed results in specific models, such as capsaicin-induced cough challenges. However, its benefit-risk profile is generally considered favorable for its approved symptomatic indications.

Common questions about Atussinum (FAQ)

Q: Does Atussinum have any effect on blood pressure?

Regulatory data indicates that Dextromethorphan, when used alone and as directed, is generally not expected to significantly alter blood pressure. However, official product information notes that combination products containing a decongestant component may potentially reduce the effectiveness of blood pressure-lowering medicines. High doses may also be associated with some cardiovascular effects.

Q: What should I do if I take too much Atussinum?

If a person suspects overexposure to Atussinum, it is necessary to seek immediate medical attention. Official safety information indicates that over-dosage may lead to severe adverse reactions, including seizures, psychosis, or respiratory depression. Emergency services, a healthcare provider, or a Poison Control Center should be contacted immediately.

Q: Is Atussinum effective for wet coughs with a lot of mucus or phlegm?

Official regulatory documents indicate that Atussinum is specifically intended only for the temporary relief of a non-productive, irritating dry cough. It is generally not recommended for a persistent or chronic cough or for a cough that is accompanied by excessive secretions or phlegm.

Q: Can I use Atussinum if I am pregnant or breastfeeding?

Official labeling and regulatory documents indicate that the safety of the active ingredient in Atussinum has generally not been established for use during pregnancy or lactation. Because the drug may pass into breast milk, use is typically not recommended unless a healthcare professional has determined it is essential after a careful risk assessment.

Q: What is the difference between Atussinum and generic Dextromethorphan?

Atussinum is a brand-name product that contains the active ingredient Dextromethorphan Hydrobromide. Generic Dextromethorphan products contain the same active ingredient and are considered to be therapeutically equivalent by the FDA, meaning they are expected to produce the same clinical effects when used as directed.

Q: How should I dispose of the leftover or expired medication?

Atussinum should not be disposed of by flushing it down a toilet or pouring it down a drain. Regulatory guidelines advise using a community pharmacy drug take-back program. If a take-back program is unavailable, official guidelines suggest mixing the medication with an unappealing substance, sealing it in a container, and discarding it in the household trash.

Q: Should I take Atussinum with food or on an empty stomach?

Official information indicates that Atussinum may generally be taken with or without food. Taking the medicine with food may help reduce the chance of experiencing any stomach upset or nausea.

Q: How long does it take for Atussinum to start working?

Pharmacokinetic data suggests that the active ingredient, Dextromethorphan, typically begins to suppress the cough reflex within 15 to 30 minutes following administration. The effects of the medicine usually last for approximately 4 to 8 hours.

Q: Does Atussinum interact with grapefruit juice?

Official labeling indicates that Dextromethorphan has the potential to interact with beverages such as grapefruit juice and Seville orange juice. These juices can prevent a key enzyme from breaking down the drug, which may increase the level of the medicine in the body and potentially raise the risk of adverse effects.

To maintain the effectiveness and safety of Atussinum, store the medication correctly and dispose of any unused or expired portions responsibly.

Storage Guidelines

Disposal

Do not dispose of expired or unwanted Atussinum by flushing it down a toilet or pouring it down a drain unless specifically instructed by the accompanying drug leaflet or a healthcare professional. The preferred method for safe disposal is through a community pharmacy take-back program or a drug collection event. If a take-back program is unavailable, mix the medication with an unappealing substance, place it in a sealed bag or container, and discard it in the household trash.